What is the recommended work‑up and management for a 67‑year‑old man with intermittent claudication (bilateral calf pain after walking one block, relieved by rest) and risk factors including a 30‑pack‑year smoking history and poorly controlled hypertension on hydrochlorothiazide?

Management of Intermittent Claudication in a 67-Year-Old Smoker

This patient requires immediate initiation of supervised exercise therapy (30–45 minutes, ≥3 times weekly for at least 12 weeks) combined with cilostazol 100 mg twice daily, aggressive cardiovascular risk reduction including high-intensity statin therapy and antiplatelet therapy, and urgent smoking cessation with pharmacologic aids. 1, 2

Diagnostic Confirmation

Before initiating therapy, confirm the diagnosis with ankle-brachial index (ABI) testing—a normal ABI (>0.90) would indicate neurogenic claudication from lumbar stenosis rather than peripheral arterial disease, fundamentally changing management. 2 The classic presentation of bilateral calf pain after one block that resolves with rest strongly suggests PAD, but ABI confirmation is mandatory. 1

First-Line Treatment: Exercise + Cilostazol

Supervised Exercise Therapy

• Supervised exercise training is the cornerstone of treatment and must be prescribed, not optional. 1, 2
• Sessions should last 30–45 minutes, performed ≥3 times per week for a minimum of 12 weeks. 1, 2
• Unsupervised or home-based programs are NOT established as effective initial therapy—simply advising the patient to "go out and walk" provides no consistent benefit. 3, 2
• Exercise should continue even if revascularization is eventually performed, as combined therapy yields the greatest functional improvement. 3, 1

Cilostazol Pharmacotherapy

• Cilostazol 100 mg orally twice daily is first-line pharmacotherapy for all patients with lifestyle-limiting intermittent claudication. 4, 1
• Cilostazol improves pain-free walking distance by 59% and maximal walking distance by 40–60% after 12–24 weeks. 4, 2
• Critical contraindication: Cilostazol is absolutely contraindicated in heart failure of any severity due to its phosphodiesterase inhibitor mechanism. 4, 1, 2
• Before prescribing, you must screen for heart failure—failing to do so is a common and dangerous pitfall. 2
• If cilostazol is contraindicated or not tolerated, pentoxifylline 400 mg three times daily with meals may be considered, but its clinical effectiveness is marginal at best. 4, 1, 2

Aggressive Cardiovascular Risk Reduction

This patient's PAD indicates systemic atherosclerosis with high risk for myocardial infarction, stroke, and cardiovascular death—cardiovascular risk reduction is as important as treating the claudication itself. 1, 2

Antiplatelet Therapy

• Aspirin 75–325 mg daily OR clopidogrel 75 mg daily should be initiated immediately to reduce risk of MI, stroke, and vascular death. 1
• Clopidogrel is a safe and effective alternative to aspirin and may be preferred in certain patients. 1
• Never add warfarin to antiplatelet therapy without another indication—this combination provides no benefit and markedly increases major bleeding risk. 1, 2

Statin Therapy

• High-intensity statin therapy is mandatory for all PAD patients, targeting LDL <100 mg/dL (or <70 mg/dL in very high-risk individuals). 1, 2
• Statin therapy reduces cardiovascular mortality independent of claudication improvement. 2

Blood Pressure Control

• Target blood pressure <140/90 mmHg (or <130/80 mmHg if diabetic or chronic kidney disease is present). 1, 2
• His current HCTZ monotherapy is inadequate given poorly controlled hypertension—consider adding an ACE inhibitor or angiotensin receptor blocker, which provide additional cardiovascular risk reduction in PAD patients. 1, 2
• Beta-blockers are NOT contraindicated in PAD and should be used when coronary artery disease is present. 1, 2

Smoking Cessation

• At every visit, ask about tobacco use and provide counseling plus a quit-plan with pharmacologic aids (varenicline, bupropion, or nicotine replacement) unless contraindicated. 1
• Smoking cessation combined with supervised exercise yields the greatest improvement in walking distance, particularly for infrainguinal lesions. 1, 2
• With a 30 pack-year history, this patient's continued smoking is the single most modifiable risk factor accelerating disease progression. 1

When to Consider Revascularization

Do NOT proceed to revascularization at this initial presentation. 1, 2

• Revascularization is indicated only after the patient has completed an adequate trial of supervised exercise and optimal medical therapy (≥3–6 months) and continues to have significant functional impairment that limits daily activities. 1, 2
• The CLEVER trial demonstrated that supervised exercise therapy and endovascular revascularization provide comparable benefits at 6 and 18 months, with each being superior to optimal medical care alone. 3
• Combining endovascular revascularization with supervised exercise provides the greatest functional improvement—approximately 78% greater improvement for aortoiliac lesions and 38% for femoropopliteal lesions at 24 months compared to exercise alone. 1, 2
• Proceeding to invasive management before an adequate trial of conservative therapy is a common pitfall to avoid. 2

Treatment Timeline & Monitoring

1. Week 0: Confirm diagnosis with ABI, screen for heart failure, initiate cilostazol 100 mg twice daily, start supervised exercise program, prescribe antiplatelet agent and high-intensity statin, intensify blood pressure control, provide smoking cessation counseling with pharmacologic aids. 4, 1, 2

2. Weeks 1–12: Continue supervised exercise therapy 3+ times weekly, monitor medication tolerance, reinforce smoking cessation at every visit. 1, 2

3. Week 12–24: Reassess functional status—if inadequate response after 12–24 weeks of optimal medical therapy, consider endovascular intervention. 4, 2

Common Pitfalls to Avoid

• Never prescribe cilostazol without confirming absence of heart failure—this is an absolute contraindication. 4, 1, 2
• Do not rely on pentoxifylline as equivalent to cilostazol—its benefit is marginal when cilostazol is contraindicated. 4, 2
• Do not prescribe unsupervised exercise or simply advise "go walk"—only supervised programs have proven efficacy. 3, 2
• Do not proceed to revascularization before 3–6 months of optimal medical therapy—this violates guideline recommendations. 1, 2
• Do not withhold beta-blockers if coronary disease is present—they are not contraindicated in PAD. 1, 2